The low molecular weight Apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: A prospective follow- up

Journal of the American Society of Nephrology

Volumn 10, Issue 5, 1999, Pages 1027-1036

  Kronenberg, Florian ^a,g   Neyer, Ulrich ^b   Lhotta, Karl ^c   Trenkwalder, Evi ^a   Auinger, Martin ^d   Pribasnig, Andreas ^e   Meisl, Thomas ^f   König, Paul ^c   Dieplinger, Hans ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b Feldkirch Hospital   (Austria)

^c UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^d GENERAL HOSPITAL LINZ   (Austria)

^e Munic Hospital of St Pölten   (Austria)

^f WILHELMINEN HOSPITAL   (Austria)

^g Inst of Med Biol and Hum Genet   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A;

ADULT; AGED; ARTICLE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART INFARCTION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL ANALYSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0032932091     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. London GM, Drücke TB: Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 51: 1678-1695, 1997
2. Kronenberg F, Dieplinger H, König P, Utermann G: Lipoprotein metabolism in renal replacement therapy: A review [Erratum published in September 1996 issue]. Isr J Med Sci 32: 371-389, 1996
3. Held PJ, Port FK, Webb RL, Wolfe RA, Bloembergen WE, Turenne MN, Holzman E, Ojo AO, Young EW, Mauger EA: Excerpts from United States Renal Data System 1995 Annual Data Report. Am J Kidney Dis 26: S1-S186, 1995
4. Kronenberg F, Utermann G, Dieplinger H: Lipoprotein(a) in renal disease. Am J Kidney Dis 27: 1-25, 1996
5. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H: Lipoprotein (a) and coronary heart disease: A prospective case-control study in a general population sample of middle aged men. Br Med J 301: 1248-1251, 1990
6. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N: Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 69: 1251-1254, 1992
7. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF: Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86: 475-482, 1992
8. Wald NJ, Law M, Watt HC, Wu TS, Bailey A, Johnson AM, Craig WY, Ledue TB, Haddow JE: Apolipoproteins and ischaemic heart disease: Implications for screening. Lancet 343: 75-79, 1994
9. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, Abolafia JM, Lippel K, Levy RI: Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 271: 999-1003, 1994
10. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D: Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: Results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 24: 444-453, 1994
11. Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PWF, Schaefer EJ, Castelli WP: Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: A prospective study. JAMA 276: 544-548, 1996
12. Wild SH, Fortmann SP, Marcovina SM: A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol 17: 239-245, 1997
13. Bostom AG, Gagnon DR, Cupples LA, Wilson PWF, Jenner JL, Ordovas JM, Schaefer EJ, Castelli WP: A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women: The Framingham Heart Study. Circulation 90: 1688-1695, 1994
14. Cantin B, Moorjani S, Després J-P, Dagenais GR, Lupien P-J: Lp(a) in ischemic heart disease. The Québec Cardiovascular Study [Abstract]. J Am Coll Cardiol 23: 482A, 1994
15. Assmann G, Schulte H, Von Eckardstein A: Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 77: 1179-1184, 1996
16. Nguyen TT, Ellefson RD, Hodge DO, Bailey KR, Kottke TE, Abu-Lebdeh HS: Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation 96: 1390-1397, 1997
17. Klausen IC, Sjol A, Hansen PS, Gerdes LU, Moller L, Lemming L, Schroll M, Faergeman O: Apolipoprotein(a) isoforms and coronary heart disease in men: A nested case-control study. Atherosclerosis 132: 77-84, 1997
18. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C: Lp(a) glycoprotein phenotypes: Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 80: 458-465, 1987
19. Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH: Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest 87: 2153-2161, 1991
20. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH: Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 90: 52-60, 1992
21. Kraft HG, Köchl S, Menzel HJ, Sandholzer C, Utermann G: The apolipoprotein(a) gene: A transcribed hypervariable locus controlling plasma lipoprotein(a) concentration. Hum Genet 90: 220-230, 1992
22. Sandholzer C, Boerwinkle E, Saha N, Tong MC, Utermann G: Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: Evidence for the role of the apo(a) gene in coronary heart disease. J Clin Invest 89: 1040-1046, 1992
23. Sandholzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, Hoppichler F, Boerwinkle E, Utermann G: Apo(a) isoforms predict risk for coronary heart disease: A study in six populations. Arterioscler Thromb 12: 1214-1226, 1992
24. Kraft HG, Lingenhel A, Köchl S, Hoppichler F, Kronenberg F, Abe A, Mühlberger V, Schönitzer D, Utermann G: Apolipoprotein(a) Kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol 16: 713-719, 1996
25. Lemming L, Klausen IC, Hansen PS, Gerdes LU, Faergeman O: Apolipoprotein(a) phenotypes in Danes with and without coronary heart disease. Nutr Metab Cardiovasc Dis 5: 231-236, 1995
26. Demeester CA, Bu X, Gray RJ, Lusis AJ, Rotter JI: Genetic variation in lipoprotein (a) levels in families enriched for coronary artery disease is determined almost entirely by the apolipoprotein (a) gene locus. Am J Hum Genet 56: 287-293, 1995
27. Kronenberg F, Kathrein H, König P, Neyer U, Sturm W, Lhotta K, Gröchenig E, Utermann G, Dieplinger H: Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb 14: 1405-1411, 1994
28. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA: Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy. Nephrol Dial Transplant 10: 354-357, 1995
29. Koch M, Kutkuhn B, Trenkwalder E, Bach D, Grabensee B, Dieplinger H, Kronenberg F: Apolipoprotein B, fibrinogen, HDL cholesterol and apo(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol 8: 1889-1898, 1997
30. Kronenberg F, König P, Neyer U, Auinger M, Pribasnig A, Lang U, Reitinger J, Pinter G, Utermann G, Dieplinger H: Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 6: 110-120, 1995
31. Kronenberg F, Lobentanz E-M, König P, Utermann G, Dieplinger H: Effect of sample storage on the measurement of lipoprotein(a), apolipoproteins B and A-IV, total and high-density lipoprotein cholesterol and triglycerides. J Lipid Res 35: 1318-1328, 1994
32. Dieplinger H, Gruber G, Krasznai K, Reschauer S, Seidel C, Burns G, Müller H-J, Császár A, Vogel W, Robenek H, Utermann G: Kringle 4 of human apolipoprotein[a] shares a linear antigenic site with human catalase. J Lipid Res 36: 813-822, 1995
33. Dieplinger H, Lackner C, Kronenberg F, Sandholzer C, Lhotta K, Hoppichler F, Graf H, König P: Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 91: 397-401, 1993
34. Kronenberg F, Trenkwalder E, Kronenberg MF, König P, Utermann G, Dieplinger H: Influence of hematocrit on the measurement of lipoproteins demonstrated by the example of lipoprotein(a). Kidney Int 54: 1385-1389, 1998
35. Kamboh MI, Ferrell RE, Kottke BA: Expressed hypervariable polymorphism of apolipoprotein (a). Am J Hum Genet 49: 1063-1074, 1991
36. Budowle B, Giusti AM, Waye JS, Baechtel FS, Fourney RM, Adams DE, Presley LA, Deadman HA, Monson KL: Fixed-bin analysis for statistical evaluation of continuous distributions of allelic data from VNTR loci, for use in forensic comparisons. Am J Hum Genet 48: 841-855, 1991
37. Mölgaard J, Klausen IC, Lassvik C, Færgeman O, Gerdes LU, Olsson AG: Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication. Arterioscler Thromb 12: 895-901, 1992
38. Kraft HG, Lingenhel A, Bader G, Kostner GM, Utermann G: The relative electrophoretic mobility of apo(a) isoforms depends on the gel system: Proposal of a nomenclature for apo(a) phenotypes. Atherosclerosis 125: 53-61, 1996
39. Appel G: Lipid abnormalities in renal disease. Kidney Int 39: 169-183, 1991
40. Zimmermann J, Herrlinger S, Pruy A, Wanner C: Mechanism of high serum lipoprotein(a) in hemodialysis patients [Abstract]. J Am Soc Nephrol 8: 260A, 1997
41. Owen WF Jr, Lew NL, Liu Y, Lowrie EG, Lazarus JM: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329: 1001-1006, 1993
42. Lowrie EG: Thoughts about judging dialysis treatment: Mathematics and measurements, mirrors in mind. Semin Nephrol 16: 242-262, 1996
43. Rostand SG, Kirk KA, Rutsky EA: Dialysis-associated ischemic heart disease: Insights from coronary angiography. Kidney Int 25: 653-659, 1984